Novo Nordisk Faces Legal Hurdles in Protecting Diabetes Drug Patents Amid Generic Competition

In the ongoing battle for market exclusivity, Novo Nordisk’s robust patent portfolio faces significant challenges from generic competitors eager to tap into the expanding Type 2 diabetes and obesity treatment sectors. Novo Nordisk’s strategy showcases the critical role of mechanisms such as abbreviated new drug application (ANDA) litigation, inter partes review, and multidistrict litigation in patent disputes. Legal professionals can gain deeper insights into these dynamics by reviewing Pedram Sameni’s analysis at Law360. It’s an essential read for those navigating the complex intersections of patent law and market competition.